Welcome to our dedicated page for Protara Therapeutics SEC filings (Ticker: TARA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Protara Therapeutics, Inc. filings document a Nasdaq-listed, Delaware clinical-stage biotechnology company developing TARA-002 for non-muscle invasive bladder cancer and lymphatic malformations, and IV Choline Chloride for patients receiving parenteral support. Form 8-K disclosures include clinical-data updates, Regulation FD materials, financial results, investor presentations, and business updates related to the company's investigational programs.
The filing record also covers Protara's capital structure and governance, including common stock registered on The Nasdaq Global Market, public offering and underwriting agreements, warrant-related disclosures, and proxy materials for annual stockholder voting. Proxy filings describe board elections, executive compensation matters, equity plans, audit oversight, and other corporate-governance proposals.
Protara Therapeutics, Inc. files its annual report describing significant progress across its oncology and rare disease pipeline. The company is developing TARA‑002, an intravesical and intracystic cell therapy, for non‑muscle invasive bladder cancer (NMIBC) and pediatric lymphatic malformations (LMs), and IV Choline Chloride for patients on long‑term parenteral support.
Interim Phase 2 ADVANCED‑2 data in NMIBC show complete response rates of 65.7% in BCG‑unresponsive and 72.4% in BCG‑naïve cohorts, with most treatment‑related events Grade 1 and transient. FDA feedback supports a registrational design for a controlled BCG‑naïve trial, and the company plans to start ADVANCED‑3 in the second half of 2026.
In LMs, Phase 2 STARBORN‑1 interim results in 12 pediatric patients showed 100% clinical success among eight evaluable patients, with most achieving meaningful volume reductions after one or two doses and a favorable safety profile. For IV Choline Chloride, Protara has FDA alignment on a registrational path, Fast Track and Orphan Drug designations, and has initiated THRIVE‑3, a seamless Phase 2b/3 trial using plasma choline change as the primary endpoint.
Protara Therapeutics reported fourth quarter and full year 2025 results while highlighting progress across its late-stage pipeline. TARA-002 showed a 68% complete response rate at six months in BCG-unresponsive non-muscle invasive bladder cancer in the ADVANCED-2 trial. The company plans to complete enrollment of this registrational cohort and start the ADVANCED-3 registrational trial in BCG-naïve patients in the second half of 2026.
For rare diseases, TARA-002 in lymphatic malformations received Breakthrough Therapy and Fast Track designations, with a regulatory update expected in the first half of 2026. Interim data from the THRIVE-3 registrational trial of IV Choline Chloride in patients on long-term parenteral support are expected in the second half of 2026. Protara completed an oversubscribed $86 million public offering and ended 2025 with about $198 million in cash, cash equivalents and investments, which it expects will fund operations into 2028. Full-year 2025 net loss was $57.4 million on operating expenses of $64.5 million, driven mainly by research and development spending.
TARA reported a Form 144 notice covering proposed sales of common stock by holders, with Canaccord Genuity LLC listed as a broker. The filing lists three sales by 667, L.P. in the past three months: 02/24/2026 26,755 shares (proceeds $161,584.00), 02/25/2026 78,716 shares (proceeds $457,046.00), and 03/04/2026 35,173 shares (proceeds $220,151.00). The filing also shows broker information for 03/06/2026.
Baker Brothers Life Sciences filed a Form 144 reporting proposed sales of Common Stock of TARA. The filing lists three brokered sales: 322,039 shares on 02/24/2026 for $1,944,922; 947,479 shares on 02/25/2026 for $5,501,316; and 424,125 shares on 03/04/2026 for $2,654,641.
Protara Therapeutics is registering up to 21,686,760 shares of common stock for resale by selling stockholders. This prospectus supplement updates the May 9, 2024 prospectus and breaks the 21,686,760 shares into 9,143,380 Initial Shares, 1,700,000 Pre-Funded Warrant Shares and 10,843,380 Common Warrant Shares.
The supplement adds selling holders and updates the selling stockholder table as of March 6, 2026, including assignments of Common Warrants for up to 200,000 warrant shares to Warberg Special Situations Fund LP and 200,000 warrant shares to Warberg WF XIII LP. Beneficial ownership limits for those holders are listed at 4.99%.
667, L.P. reported sales of Common Stock for TARA. The filing shows sales of 26,755 shares on 02/24/2026 for $161,584.00 and 78,716 shares on 02/25/2026 for $457,046.00.
The transactions are listed through a broker (Canaccord Genuity LLC) on 03/04/2026.
Baker Brothers Life Sciences filed a Form 144 reporting proposed sales of Common Stock by broker. The filing lists proposed brokered transactions through Canaccord Genuity with a broker date of 03/04/2026. The record lists sales of 322,039 shares on 02/24/2026 and 947,479 shares on 02/25/2026. A line in the filing shows 53,587,260 shares with the date 03/04/2026 listed nearby.
Protara Therapeutics Schedule 13G: Millennium group reports shared ownership of 2,759,231 common shares (5.1%). The filing states that Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander share voting and dispositive power over 2,759,231 shares of Protara Therapeutics common stock as of 02/25/2026. A Joint Filing Agreement dated 02/27/2026 is attached, and signatures by representatives, including Israel A. Englander, are included.
667, L.P. reported the sale of 26,755 shares of Common Stock. The Form 144 excerpt lists a sale date of 02/24/2026 and a reported value of $161,584.00.
The filing names Canaccord Genuity LLC as a broker and includes additional trade dates of 12/08/2025 and 02/25/2026 in the securities table.
TARA: A Form 144 filing reports planned or completed dispositions of Common Stock by selling holders. The filing shows a sale of 322,039 shares by Baker Brothers Life Sciences, L.P. on 02/24/2026. It also lists proposed methods and additional sale quantities including 24,186 shares (underwriter) dated 12/08/2025 and 923,293 shares (broker) dated 02/25/2026.
The filing lists intermediaries such as Canaccord Genuity LLC and identifies NASDAQ as the exchange. These entries indicate registered resale activity by institutional holders rather than corporate actions by the issuer.